• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

    2/14/22 9:40:24 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email
    SC 13G/A 1 CamberColl-202113G.htm PRIMARY DOCUMENT  
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)
     
    Collegium Pharmaceutical, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    19459J104
    (CUSIP Number)
     
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☒  Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
    Persons who respond to the collection of information contained in this form are not
    required to respond unless the form displays a currently valid OMB control number.
     
    13G
    CUSIP No. 19459J104
    Page 2 of 6
     
                                                 
    1. Names of Reporting Persons.
    Camber Capital Management LP
    42-1693587
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Delaware
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    1,050,000 shares
     
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    1,050,000 shares
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Camber Capital Management LP – 1,050,000 shares
        10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Camber Capital Management LP – 3.04%
    12. Type of Reporting Person
    Camber Capital Management LP – 00 (Limited Partnership)
     
    13G
    CUSIP No.   19459J104
    Page 3 of 6

    1. Names of Reporting Persons.
    Stephen DuBois
    Not applicable
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Stephen DuBois – United States
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    1,050,000 shares
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    1,050,000 shares
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Stephen DuBois – 1,050,000 shares
       10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Stephen DuBois – 3.04%
    12. Type of Reporting Person
    Stephen DuBois – IN
     
    13G
      CUSIP No.   19459J104
    Page 4 of 6
     
     
     
    ITEM 1.
    (a) Name of Issuer:
    Collegium Pharmaceutical, Inc.
     
    (b) Address of Issuer's Principal Executive Offices:
    100 Technology Center Drive, Stoughton, MA 02072
     
    ITEM 2.
    (a) Name of Person Filing:
    Camber Capital Management LP
    Stephen DuBois
     
    (b) Address of Principal Business Office, or if None, Residence:
    Camber Capital Management LP
    Stephen DuBois
    101 Huntington Avenue
    Suite 2101
    Boston, MA 02199
     
    (c) Citizenship:
    Camber Capital Management LP – Delaware
    Stephen DuBois – United States
     
    (d) Title of Class of Securities:
    Common Stock, par value $0.001 per share
     
    (e) CUSIP Number:
    19459J104
     
     
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
     
     
    (a)
    [_]
    Broker or dealer registered under Section 15 of the Act  (15 U.S.C. 78o).
     
    (b)
    [_]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).   
     
    (c)
    [_]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).   
     
    (d)
    [_]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [_]
    An investment adviser in accordance with  ss.240.13d-1(b)(1)(ii)(E);   
     
    (f)
    [_]
    An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);   
     
    (g)
    [_]
    A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);   
     
    (h)
    [_]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);   
     
    (i)
    [_]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);   
     
    (j)
    [_]
    Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
     
    ITEM 4. OWNERSHIP.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
    (a) Amount beneficially owned: Camber Capital Management LP – 1,050,000 shares
    Stephen DuBois – 1,050,000 shares
     
    (b) Percent of class: Camber Capital Management LP – 3.04% 
    Stephen DuBois – 3.04%
     
     
    13G
       CUSIP No.   19459J104
    Page 5 of 6
     
    (c) Number of shares as to which such person has:
     
    (i) Sole power to vote or to direct the vote
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (ii) Shared power to vote or to direct the vote
    Camber Capital Management LP – 1,050,000 shares
    Stephen DuBois – 1,050,000 shares
     
    (iii) Sole power to dispose or to direct the disposition of
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (iv) Shared power to dispose or to direct the disposition of
    Camber Capital Management LP – 1,050,000 shares
    Stephen DuBois – 1,050,000 shares
     
     
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ x].
     
    INSTRUCTION: Dissolution of a group requires a response to this item.
     
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
     
    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
     
    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
     
     
    13G
    CUSIP No.   19459J104
    Page 6 of 6
     
     
     
    ITEM 10. CERTIFICATIONS.
    The following certification shall be included if the statement is filed pursuant to S.240.13d-1(c):
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
     
     
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    CAMBER CAPITAL MANAGEMENT LP
    By: /s/Sean George
    Sean George
    Chief Financial Officer
     
    STEPHEN DUBOIS
    By: /s/ Stephen DuBois
    Stephen DuBois, individually
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
     
     
    Get the next $COLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    5/2/2023$30.00Buy
    Jefferies
    More analyst ratings

    $COLL
    SEC Filings

    See more
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/19/25 4:05:20 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.

      SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      5/14/25 4:04:49 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Other Events

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/12/25 8:10:35 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Collegium Pharmaceutical upgraded by Needham with a new price target

      Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

      1/10/25 8:00:15 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

      7/30/24 6:32:12 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by Jefferies with a new price target

      Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously

      6/7/24 7:29:08 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

      SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 5:13:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 4:30:24 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/14/24 12:04:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fallon John A. was granted 9,791 shares, increasing direct ownership by 18% to 64,634 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:43:54 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lurker Nancy was granted 9,791 shares, increasing direct ownership by 77% to 22,517 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:43:15 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bohlin Garen G was granted 9,791 shares, increasing direct ownership by 19% to 62,259 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:42:47 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Financials

    Live finance-specific insights

    See more

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $COLL
    Leadership Updates

    Live Leadership Updates

    See more
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

      STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Compa

      4/24/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

      – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON,

      2/27/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Participate in Upcoming Investor Conferences

      STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharm

      5/19/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces $25 Million Accelerated Share Repurchase Program

      STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program. "Collegium is off to a strong start in 2025 with first quarter revenues g

      5/12/25 8:05:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces Updates to its Board of Directors and Executive Leadership Team

             – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

      3/17/25 7:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Appoints Nancy S. Lurker to its Board of Directors

      STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

      2/5/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care